Maxim Group Maintains a Buy Rating on Bellerophon (BLPH)

By Jason Carr

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Bellerophon (BLPHResearch Report), with a price target of $2.00. The company’s shares closed last Monday at $0.44, close to its 52-week low of $0.37.

According to, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -20.7% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Bellerophon has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.

See today’s analyst top recommended stocks >>

Based on Bellerophon’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.11 million. In comparison, last year the company had a net profit of $11.1 million.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.